share_log

Connect Biopharma | 6-K: Report of foreign private issuer (related to financial reporting)

Connect Biopharma | 6-K: Report of foreign private issuer (related to financial reporting)

康乃德生物 | 6-K:外国发行人报告(业绩相关)
美股sec公告 ·  06/12 16:52
Moomoo AI 已提取核心信息
Connect Biopharma Holdings Limited has announced significant changes in its executive leadership. On June 10, 2024, Zheng Wei, Ph.D., and Wubin Pan, Ph.D., communicated their intentions to resign from their respective roles as Chief Executive Officer and President of the company, effective June 12, 2024. Both executives are expected to continue serving in a transitional capacity post-resignation. Concurrently, the Board appointed Kleanthis G. Xanthopoulos, Ph.D., as the new Chairperson of the Board. Furthermore, Barry Quart, Pharm.D., with a notable background including leadership roles at Heron Therapeutics and Ardea Biosciences, has been appointed as the new CEO and a member of the Board. David Szekeres, with previous experience at Heron Therapeutics and Regulus Therapeutics, has been named the new President...Show More
Connect Biopharma Holdings Limited has announced significant changes in its executive leadership. On June 10, 2024, Zheng Wei, Ph.D., and Wubin Pan, Ph.D., communicated their intentions to resign from their respective roles as Chief Executive Officer and President of the company, effective June 12, 2024. Both executives are expected to continue serving in a transitional capacity post-resignation. Concurrently, the Board appointed Kleanthis G. Xanthopoulos, Ph.D., as the new Chairperson of the Board. Furthermore, Barry Quart, Pharm.D., with a notable background including leadership roles at Heron Therapeutics and Ardea Biosciences, has been appointed as the new CEO and a member of the Board. David Szekeres, with previous experience at Heron Therapeutics and Regulus Therapeutics, has been named the new President. These appointments coincide with the adoption of the 2024 Employment Inducement Incentive Award Plan, which is designed to provide incentives to new employees under Nasdaq rules. The plan initially reserves 4,500,000 shares for issuance under awards. The company has also entered into employment agreements with Dr. Quart and Mr. Szekeres, detailing their compensation, bonus eligibility, and severance terms.
连接生物医药控股有限公司宣布其高管领导层发生重大变动。2024年6月10日,郑玮博士和潘武斌博士分别通知其将于2024年6月12日生效辞去公司首席执行官和总裁职务,预计两位高管将在辞职后继续担任过渡期职务。同时,董事会任命Kleanthis G. Xanthopoulos博士为新任主席。此外,Barry Quart博士被任命为新的首席执行官和董事会成员,他曾在Heron Therapeutics和Ardea Biosciences担任领导职务。David Szekeres则被任命为新的总裁,他曾在Heron Therapeutics和regulus therapeutics任职。这些任命与采纳2024雇佣引诱激励计划同时发生,该计划旨在根据纳斯达克规则为新员工提供激励措施。该计划最初保留了450万股股份以供颁发授予。公司还与Quart博士和Szekeres先生签订了就业协议,详细说明了他们的补偿、奖金资格和离职条款。
连接生物医药控股有限公司宣布其高管领导层发生重大变动。2024年6月10日,郑玮博士和潘武斌博士分别通知其将于2024年6月12日生效辞去公司首席执行官和总裁职务,预计两位高管将在辞职后继续担任过渡期职务。同时,董事会任命Kleanthis G. Xanthopoulos博士为新任主席。此外,Barry Quart博士被任命为新的首席执行官和董事会成员,他曾在Heron Therapeutics和Ardea Biosciences担任领导职务。David Szekeres则被任命为新的总裁,他曾在Heron Therapeutics和regulus therapeutics任职。这些任命与采纳2024雇佣引诱激励计划同时发生,该计划旨在根据纳斯达克规则为新员工提供激励措施。该计划最初保留了450万股股份以供颁发授予。公司还与Quart博士和Szekeres先生签订了就业协议,详细说明了他们的补偿、奖金资格和离职条款。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息